ENB-003
Ovarian Cancer (in combination with toripalimab)
Phase 1/2Active
Key Facts
Indication
Ovarian Cancer (in combination with toripalimab)
Phase
Phase 1/2
Status
Active
Company
About ENB Therapeutics
ENB Therapeutics is an emerging oncology biotech advancing ENB-003, a small molecule designed to modulate the tumor microenvironment, potentially overcoming resistance to checkpoint inhibitors. Its strategy is validated by a clinical collaboration with Coherus BioSciences and the Cancer Research Institute to combine ENB-003 with toripalimab in ovarian cancer. The company is pre-revenue, privately held, and operates with a lean structure, leveraging partnerships to advance its pipeline. Its success hinges on demonstrating clinical proof-of-concept for its novel mechanism in a challenging indication.
View full company profile